Based on the Lyxor NYSE Arca Gold BUGS (DR) UCITS ETF stock forecast from 0 analysts, the average analyst target price for Lyxor NYSE Arca Gold BUGS (DR) UCITS ETF is not available over the next 12 months. Lyxor NYSE Arca Gold BUGS (DR) UCITS ETF’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Lyxor NYSE Arca Gold BUGS (DR) UCITS ETF is Very Bearish, which is based on 0 positive signals and 3 negative signals. At the last closing, Lyxor NYSE Arca Gold BUGS (DR) UCITS ETF’s stock price was EUR 28.96. Lyxor NYSE Arca Gold BUGS (DR) UCITS ETF’s stock price has changed by +9.82% over the past week, -4.38% over the past month and +43.76% over the last year.
No recent analyst target price found for Lyxor NYSE Arca Gold BUGS (DR) UCITS ETF
No recent average analyst rating found for Lyxor NYSE Arca Gold BUGS (DR) UCITS ETF
Company Overview Lyxor NYSE Arca Gold BUGS (DR) UCITS ETF
Stock Target Advisor's fundamental analysis for Lyxor NYSE Arca Gold BUGS (DR) UCITS ETF's stock is Very Bearish.
CD91:F stock's dividend yield is 2.82%.
Our analysis grades CD91:F stock's dividend yield at F. This means that CD91:F stock's dividend yield is above 42% of the stocks in the Others sector in the F exchange.
Based on this CD91:F may be a average dividend stock for its sector.
Unfortunately we do not have enough data on CD91:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on CD91:F's stock to indicate if its overvalued.
The last closing price of CD91:F's stock was EUR 28.96.
The most recent market capitalization for CD91:F is EUR 0.31B.
Unfortunately we do not have enough analyst data on CD91:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Lyxor NYSE Arca Gold BUGS (DR) UCITS ETF's stock.
Sorry, we do not have any data on the number of employees for Lyxor NYSE Arca Gold BUGS (DR) UCITS ETF.
Sorry we do not have any infomation available on Lyxor NYSE Arca Gold BUGS (DR) UCITS ETF's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Stock Target Advisor's fundamental analysis for Lyxor NYSE Arca Gold BUGS (DR) UCITS ETF's stock is Very Bearish.
CD91:F stock's dividend yield is 2.82%.
Our analysis grades CD91:F stock's dividend yield at F. This means that CD91:F stock's dividend yield is above 42% of the stocks in the Others sector in the F exchange.
Based on this CD91:F may be a average dividend stock for its sector.
Unfortunately we do not have enough data on CD91:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on CD91:F's stock to indicate if its overvalued.
The last closing price of CD91:F's stock was EUR 28.96.
The most recent market capitalization for CD91:F is EUR 0.31B.
Unfortunately we do not have enough analyst data on CD91:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Lyxor NYSE Arca Gold BUGS (DR) UCITS ETF's stock.
Sorry, we do not have any data on the number of employees for Lyxor NYSE Arca Gold BUGS (DR) UCITS ETF.
Sorry we do not have any infomation available on Lyxor NYSE Arca Gold BUGS (DR) UCITS ETF's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CD91:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
